Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Preventive Tirofiban for Early Neurological Deterioration in Acute Ischemic Stroke Without Thrombolysis or Thrombectomy.

Created on 07 Nov 2026

Authors

Jingyu Shi, Jing Cai, Yongxue Hu, Yuanhua Wu

Published in

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. Pages 108782. Nov 06, 2026. Epub Nov 06, 2026.

Abstract

We assessed whether preventive intravenous tirofiban reduces early neurological deterioration (END) in acute ischemic stroke without thrombolysis or thrombectomy, and how population, timing and comparator differences affect interpretation.
A focused evidence update included PubMed searching through October 13, 2026, screening of 520 records and citation checks. Randomized and observational evidence were separated. Risk ratios (RRs) were analyzed using restricted maximum-likelihood models, with fixed-effect, Hartung-Knapp, prediction-interval and influence analyses. Abstract-level evidence was evaluated separately where eligibility was uncertain.
Two randomized trials (1,395 participants) yielded discordant END estimates: RR 0.50 (95% CI 0.32-0.77) and 0.91 (0.67-1.22). The exploratory pooled RR was 0.69 (0.38-1.24; I²=79.6%; τ²=0.143), with marked model dependence. Four trials contributed 2,017 observed 90-day modified Rankin Scale 0-1 outcomes: RR 1.12 (1.05-1.19); modified Hartung-Knapp CI 1.01-1.23 and prediction interval 0.98-1.28. Excluding ESCAPIST because of discrepant published counts widened the modified Hartung-Knapp interval to 0.96-1.27. Separately, the BRANT abstract reported RR 1.01 (0.90-1.13); target-population eligibility was unconfirmed. Treatment-by-time interactions and mediation of functional benefit through END prevention were not established.
Preventive END effects are trial-specific. The functional signal is sensitive to source and model assumptions and does not establish END-mediated benefit. Imaging-guided selection and incremental benefit over optimized oral therapy require direct randomized evaluation, with standardized neurological, functional and bleeding outcomes.

PMID:
42994514
Bibliographic data and abstract were imported from PubMed on 07 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement